This is a paid press release. Contact the press release distributor directly with any inquiries.
Alzai Health Corp. Announces Marketing Services Agreement
- ALZI.V
- H2F.F
Toronto, Ontario–(Newsfile Corp. – August 17, 2026) – Alzai Health Corp. (TSXV: ALZI) (the “Company” or “ALZAI”) announces that it has entered into a services agreement dated August 12, 2026 (the “Services Agreement”) with Euro Digital Media Ltd. (“Euro Digital”) (address: 71-75 Shelton Street, Covent Garden, London, UK WC2H 9JQ) pursuant to which Euro Digital will provide market awareness and digital marketing services to the Company.
Under the terms of the Services Agreement, Euro Digital will create campaigns, ad groups, text ads and display ads, perform detailed keyword research, develop and manage remarketing campaigns, dynamically optimize keyword sets, conduct ongoing bid management, optimize keyword options, coordinate with online advertisers and marketers corresponding to the Company’s online marketing objectives, place display advertisements, and create landing pages for advertising campaigns (the “Services”).
The Company has agreed to pay Euro Digital a fee of US$425,000, plus any applicable local taxes, for the Services. The Services are expected to be provided over a term of 12 months following TSX Approval (defined below), or until budget exhaustion, whichever occurs first.
The Company will not issue any securities to Euro Digital as compensation for its marketing services. As of the date hereof, to the Company’s knowledge, Euro Digital, including its principal, does not own any securities of the Company and has an arm’s length relationship with the Company. The Services Agreement is subject to the approval of the TSX Venture Exchange (“TSXV Approval”).
About Alzai Health Corp.
ALZAI Health Corp. is a healthcare technology company developing non-invasive, artificial intelligence-driven disease risk identification solutions using routine healthcare data. The Company’s proprietary platform is designed to identify individuals at elevated risk for disease before clinical diagnosis, enabling earlier intervention opportunities and supporting improved patient outcomes. ALZAI’s technology has been validated on large-scale healthcare datasets and is designed for integration into existing healthcare infrastructure, including electronic medical record systems, cloud-based environments, and enterprise healthcare platforms.
FOR FURTHER INFORMATION, PLEASE CONTACT:
Hayim Raclaw
Chairman and Chief Executive Officer
Alzai Health Corp.
Email: info@alzaihealth.com
Telephone: 416-862-4351
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
